Literature DB >> 25636446

High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis.

HeLi Gao1, Mei Guan, Zhao Sun, ChunMei Bai.   

Abstract

Recent studies have shown that c-Met is an important signal in the development of colorectal cancer, but the prognostic value of c-Met remains unclear. We aimed to analyze the prognostic effect of c-Met in colorectal cancer through a systematic review and meta-analysis. Through database searches, we identified six articles describing how c-Met status affects colorectal cancer prognosis. A meta-analysis was performed to investigate the relationship between the hazard ratio and survival. The available outcome data from six articles were examined. A meta-analysis of the HR and the 95% confidence interval (CI) indicated a significantly poor overall survival and disease-free survival in patients with high expression levels of c-Met. The subgroup analysis showed that the prognostic effect of the c-Met level was similar in different methods and was not associated with disease stages. High c-Met expression levels could predict a poor prognosis in colorectal cancer patients. The c-Met status could be used to evaluate the prognosis in clinical patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25636446     DOI: 10.1007/s13277-014-2659-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma.

Authors:  A A Abou-Bakr; A Elbasmi
Journal:  Gulf J Oncolog       Date:  2013-07

2.  Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

Authors:  Alessandro Inno; Mariantonietta Di Salvatore; Tonia Cenci; Maurizio Martini; Armando Orlandi; Antonia Strippoli; Anna Maria Ferrara; Cinzia Bagalà; Alessandra Cassano; Luigi Maria Larocca; Carlo Barone
Journal:  Clin Colorectal Cancer       Date:  2011-05-11       Impact factor: 4.481

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

5.  Multivariate analysis of molecular indicators for postoperative liver metastasis in colorectal cancer cases.

Authors:  Li-Yuan Qian; Ping Li; Xiao-Rong Li; Dao-Jin Chen; Shai-Hong Zhu
Journal:  Asian Pac J Cancer Prev       Date:  2012

6.  Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis--correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met.

Authors:  Alexandros Garouniatis; Adamantia Zizi-Sermpetzoglou; Spyros Rizos; Alkiviadis Kostakis; Nikolaos Nikiteas; Athanasios G Papavassiliou
Journal:  Tumour Biol       Date:  2013-04-12

7.  Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.

Authors:  U Coskun; N Bukan; B Sancak; N Günel; S Ozenirler; A Unal; A Yucel
Journal:  Neoplasma       Date:  2004       Impact factor: 2.575

Review 8.  Molecular cancer therapy: can our expectation be MET?

Authors:  Cristina Migliore; Silvia Giordano
Journal:  Eur J Cancer       Date:  2008-03-04       Impact factor: 9.162

9.  MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality.

Authors:  Antônio Talvane Torres De Oliveira; Delcio Matos; Angela Flávia Logullo; Sandra Regina Morini DA Silva; Ricardo Artigiani Neto; Adhemar Longatto Filho; Sarhan Sydney Saad
Journal:  Anticancer Res       Date:  2009-11       Impact factor: 2.480

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  16 in total

1.  Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Authors:  Simona Cignetto; Chiara Modica; Cristina Chiriaco; Lara Fontani; Paola Milla; Paolo Michieli; Paolo M Comoglio; Elisa Vigna
Journal:  Mol Oncol       Date:  2016-03-28       Impact factor: 6.603

Review 2.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

3.  Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland.

Authors:  Diana Bell; Renata Ferrarotto; Melanie D Fox; Dianna Roberts; Ehab Y Hanna; Randal S Weber; Adel K El-Naggar
Journal:  Cancer Biol Ther       Date:  2015-04-29       Impact factor: 4.742

4.  Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.

Authors:  Jingquan Jia; Lauren Howard; Yingmiao Liu; Mark D Starr; John C Brady; Donna Niedzwiecki; John H Strickler; Andrew B Nixon
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-16       Impact factor: 3.333

5.  Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy.

Authors:  Cristina Chiriaco; Chiara Donini; Valeria Leuci; Elisa Vigna; Marco Cortese; Stefano Ughetto; Chiara Modica; Ilaria Martinelli; Alessia Proment; Letizia Vitali; Lara Fontani; Monica Casucci; Paolo Maria Comoglio; Silvia Giordano; Dario Sangiolo
Journal:  J Exp Clin Cancer Res       Date:  2022-10-21

6.  Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients.

Authors:  An Na Seo; Kyoung Un Park; Gheeyoung Choe; Woo Ho Kim; Duck-Woo Kim; Sung-Bum Kang; Hye Seung Lee
Journal:  Tumour Biol       Date:  2015-07-10

7.  First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.

Authors:  Aiwu Ruth He; Roger B Cohen; Crystal S Denlinger; Ashwin Sama; Ariel Birnbaum; Jimmy Hwang; Takami Sato; Nancy Lewis; Michelle Mynderse; Michele Niland; Jennifer Giles; Johan Wallin; Brian Moser; Wei Zhang; Richard Walgren; Elizabeth R Plimack
Journal:  Oncologist       Date:  2019-03-04

Review 8.  Endogenous retroviral promoter exaptation in human cancer.

Authors:  Artem Babaian; Dixie L Mager
Journal:  Mob DNA       Date:  2016-12-01

9.  Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis.

Authors:  Chao-Yuan Huang; Qian-Yi Zhou; Yue Hu; Yi Wen; Zhen-Wen Qiu; Man-Guang Liang; Jun-Ling Mo; Jian-Hua Xu; Cong Sun; Feng-Bin Liu; Xin-Lin Chen
Journal:  Oncotarget       Date:  2017-04-04

10.  CITED4 gene silencing in colorectal cancer cells modulates adherens/tight junction gene expression and reduces cell proliferation.

Authors:  Michael A Rogers; Verena Kalter; Gemma Marcias; Marc Zapatka; Sebastian Barbus; Peter Lichter
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-05       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.